Please login to the form below

biologic

This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

Tezspire is the only biologic that targets TSLP, shown to play a key role in multiple inflammatory pathways in the condition. ... of biomarker status or phenotype, opening up biologics as a treatment option for many patients across England and Wales who

Latest news

Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility

The biologics manufacturing site is expected to create more than 300 highly skilled jobs. ... Eli Lilly has said it will be doubling the planned investment in its new biologics manufacturing facility in Ireland, bringing the total spend up to almost $1bn.
Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Naimish Patel, head of global development, immunology and inflammation at Sanofi, said: “With this latest approval, Dupixent is the first-ever biologic medicine for people living with atopic dermatitis from infancy
UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients

There is currently only one approved biologic treatment for the inflammatory skin disease. ... Currently, there is only one approved biologic treatment for HS. UCB’s bimekizumab is designed to selectively inhibit both IL-17A and IL-17F, two key
Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

Zerhouni, president and vice chairman of Opko, said: “We founded ModeX to develop innovative multi specific biologics for cancer and infectious diseases that target multifactorial pathways that cause illness.
FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Eisai’s supplemental biologics application for approval under the traditional pathway is now supported by data from the phase 3 confirmatory Clarity AD clinical trial.

More from news
Approximately 25 fully matching, plus 724 partially matching documents found.

Latest Intelligence

A relentless commitment to neuroscience

Technologies that facilitate and enhance transfer of biologics across the blood-brain barrier are also progressing at an exciting pace.
Biosimilars and beyond: innovating for improved patient outcomes

One of the ways Celltrion Healthcare has done this is by increasing patient access to innovative biologics, and the company remains focused on this in 2023. ... The past decade – and 2022 in particular – has laid great foundations for progress in the
How diversity and inclusion continues to be incorporated in dermatology

References. 1 Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
How early-stage clinical research is facilitating the new wave of personalised medicines

is also being used to treat autoimmune and cardiac conditions, and biologic medicines, which now account for 15% of medicines prescribed in Japan and 30% in the USA (in 2018).
Piloting a route to the biosimilars opportunities in Europe

These products might take 30-50% less time to develop, and cost up to 70% less than their biologic originals – savings that can be passed on to healthcare providers and patients. ... The increased competition also forces originator/biologic

More from intelligence
Approximately 5 fully matching, plus 93 partially matching documents found.

Latest appointments

Ex-BMS exec jumps to Gilead to lead research group

That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
New hires at Crescendo, Healx and Galecto

The latest movers in pharma. Crescendo. Crescendo Biologics has appointed Kenji Hashimoto as its new chief medical officer, who joins Crescendo with over 15 years of experience in oncology and ... Kenji has considerable immuno-oncology expertise and an
New hires at FibroGen, Saniona and Turbine

Tuna currently serves as chief scientific officer at Adaptate Biotherapeutics, and has over 15 years of experience in biologics drug discovery and development.
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... A champion for science and
BMS appoints new commercial leader, Davies joins Eisai and more

Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.

More from appointments
Approximately 8 fully matching, plus 48 partially matching documents found.

Latest from PMHub

The future of nanomedicine regulation

By putting products into different boxes (e.g. chemical drugs versus biologics), regulators have managed to develop very clear processes that are tailored to the unique characteristics of different treatment types.
Why you should feel optimistic about the future of healthcare

CytImmune Sciences recently completed a Phase I trial using gold nanoparticles to target drug delivery to tumours; BlueWillow Biologics has developed nanotech that fights viruses and bacteria.
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell
Integrated NHS finances: what do they mean for High Cost Drugs?

So, those with High Cost biologics are going to have to think carefully about their value proposition.
Living with psoriasis: a patient perspective

million[i]) received a biologic therapy in the UK in 2012.

More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.

Subscribe to our email news alerts

Pharmacovigilance Project Lead: Highly competitive salary

Technical Sales Representative: Highly competitive salary

Pharmacovigilance Manager: Highly competitive salary

Strategy Director - Healthcare Advertising: £90,000 - £120,000 yearly

Senior Medical Writer: Highly competitive salary

Omnichannel Account Director: £55,000 - £65,000 yearly

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: £100,000 - £115,000 yearly

PMHub

Add my company

Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Time to talk about health inequalities: Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms: Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Email:
Password:

Please login to the form below

biologic

Subscribe to our email news alerts

Quick links